Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

Congress meeting · Dr. Oscar Petit

23 Jan 2026 · In person · Dr. Oscar Petit, Ospedale San Raffaele · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0025—

Capture insight from this engagement

Location: Ospedale San Raffaele
Therapeutic area: Oncology
Country: Italy
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Chemotherapy-free first line

Scientific content used

PD-L1 testing pathway infographic

Questions raised

What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Congress meeting with oncology pharmacist at Ospedale San Raffaele. Discussed chemotherapy-free first line.

Insights captured (1)

Capture insight

INS-0063Medium
Chemotherapy-free first line
Chemotherapy-free first line: interest in collaboration reported by oncology pharmacist (IT).
Deduplicated

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 4
Depth of exchange: 3
Actionability: 5

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0025

Audit history (1)

All create, update and approval events for this record

Time	Action	User	Field	Change	Reason	Source
11 Sept 2026, 10:14 UTC	Update	DCDavid Chen	topics	Planned → Completed	—	UI